Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
PRNewswire - December 18, 2001
TAG is a privately held national distributor to the U.S. public Sector and currently serves over 2,500 customers, including state and local health departments, community based organizations, HIV/ STD Prevention organizations, Planned Parenthood Clinics, and family planning organizations.
TAG is dedicated to enabling Safer-Sex and Family planning Organizations to distribute the highest quality prevention and education materials. As a one stop source to the public sector for major brands of condoms, lubricants, and safer sex educational materials, TAG is a full service distributor providing marketing, education, and customer service support.
"TAG's existing network is an ideal vehicle to communicate about, build awareness of and increase the use of the FC Female Condom in the US", said Mary Ann Leeper, FHC's President. "Today's announcement is part of FHC's on- going strategy to partner with organizations to assist in bringing the female condom to women in their communities", she continued.
FHC will continue to maintain public sector sales for the remaining states and will also provide training and educational out-reach programming which it has successfully developed since the FC Female Condom was first introduced in the US.
The Female Condom is the only product controlled by women that helps to prevent STDs, including HIV/AIDS and unintended pregnancy. It is made of polyurethane, which is strong and unlikely to rip or tear during use and unlikely to cause allergic reactions. It is manufactured in a state of the art facility in London, England.
The Female Health Company, based in Chicago, owns certain worldwide rights to The Female Condom(TM), including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, The People's Republic of China, Canada, New Zealand, South Korea and Australia.
"Safe Harbor" Statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of governmental regulations, both in the United States and abroad; the effects of competitive products and pricing pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.
For more information about the Female Health Company, dial toll-free via fax, 1-800-PRO-INFO and enter company code "FHCO." Also, visit FHC's Websites at http://www.femalehealth.com and http://www.femalecondom.org .
011218
PR011241
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .